1-18 of 18
Philip Home
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Julio Rosenstock, Antonio Nino, Joseph Soffer, Lois Erskine, Andre Acusta, Jo Dole, Molly C. Carr, Jason Mallory, Philip Home
Journal: Diabetes Care
Diabetes Care 2020;43(10):2509–2518
https://doi.org/10.2337/dc19-2316
Published: 21 July 2020
View article titled, Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
Open the PDF for Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial in another window
Journal Articles

How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?

Philip Home
Journal: Diabetes Care
Diabetes Care 2020;43(2):272–274
https://doi.org/10.2337/dci19-0056
Published: 13 January 2020
View article titled, How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?
Open the PDF for How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials? in another window
Journal Articles

Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground

Philip Home
Journal: Diabetes Care
Diabetes Care 2019;42(9):1615–1623
https://doi.org/10.2337/dci19-0002
Published: 08 June 2019
View article titled, Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground
Open the PDF for Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground in another window
Journal Articles

Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655–662

Philip Home, John Lachin
Journal: Diabetes Care
Diabetes Care 2018;41(4):e64
https://doi.org/10.2337/dc17-2405
Published: 12 March 2018
View article titled, Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655–662
Open the PDF for Comment on Novodvorsky et al. Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes. Diabetes Care 2017;40:655–662 in another window
Journal Articles

George Alberti: A Myriad of Contributions to Diabetes and Beyond

Philip Home
Journal: Diabetes Care
Diabetes Care 2017;40(9):1154–1158
https://doi.org/10.2337/dci17-0006
Published: 14 August 2017
View article titled, George Alberti: A Myriad of Contributions to Diabetes and Beyond
Open the PDF for George Alberti: A Myriad of Contributions to Diabetes and Beyond in another window
Journal Articles

Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?

Philip Home
Journal: Diabetes Care
Diabetes Care 2015;38(12):2234–2236
https://doi.org/10.2337/dc15-1046
Published: 19 November 2015
View article titled, Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?
Open the PDF for Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose? in another window
Journal Articles

Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research

Oliver Schnell, Katharine Barnard, Richard Bergenstal, Emanuele Bosi, Satish Garg, Bruno Guerci, Thomas Haak, Irl B. Hirsch, Linong Ji, Sashank R. Joshi, Maarten Kamp, Lori Laffel, Chantal Mathieu, William H. Polonsky, Frank Snoek, Philip Home
Journal: Diabetes Care
Diabetes Care 2015;38(9):1627–1633
https://doi.org/10.2337/dc14-2919
Published: 10 August 2015
View article titled, Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research
Open the PDF for Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research in another window
Journal Articles

Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation

Augustin M. Brooks, Richard Oram, Philip Home, Nick Steen, James A.M. Shaw
Journal: Diabetes Care
Diabetes Care 2015;38(1):105–112
https://doi.org/10.2337/dc14-1656
Published: 24 November 2014
View article titled, Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation
Open the PDF for Demonstration of an Intrinsic Relationship Between Endogenous C-Peptide Concentration and Determinants of Glycemic Control in Type 1 Diabetes Following Islet Transplantation in another window
Journal Articles

Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508

Philip Home, Matthew Riddle, William T. Cefalu, Clifford J. Bailey, Reinhard G. Bretzel, Stefano del Prato, Derek Leroith, Guntram Schernthaner, Luc van Gaal, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2014;37(11):e247
https://doi.org/10.2337/dc14-1790
Published: 10 October 2014
View article titled, Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508
Open the PDF for Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508 in another window
Journal Articles

Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?

Philip Home, Matthew Riddle, William T. Cefalu, Clifford J. Bailey, Reinhard G. Bretzel, Stefano del Prato, Derek Leroith, Guntram Schernthaner, Luc van Gaal, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2014;37(6):1499–1508
https://doi.org/10.2337/dc13-2743
Published: 10 May 2014
View article titled, Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
Open the PDF for Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? in another window
Journal Articles

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)

Matthew C. Riddle, MD, Ronnie Aronson, MD, FRCPC, FACE, Philip Home, DPHIL, DM, FRCP, Michel Marre, MD, PHD, Elisabeth Niemoeller, MD, Patrick Miossec, MD, Lin Ping, MD, Jenny Ye, Julio Rosenstock, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2489–2496
https://doi.org/10.2337/dc12-2454
Published: 13 August 2013
View article titled, Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: <subtitle>A 24-week, randomized, placebo-controlled comparison (GetGoal-L)</subtitle>
Open the PDF for Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: <subtitle>A 24-week, randomized, placebo-controlled comparison (GetGoal-L)</subtitle> in another window
Includes: Supplementary data
Journal Articles

Insulin Therapy and Cancer

Philip Home, DM
Journal: Diabetes Care
Diabetes Care 2013;36(Supplement_2):S240–S244
https://doi.org/10.2337/dcS13-2002
Published: 17 July 2013
View article titled, Insulin Therapy and Cancer
Open the PDF for Insulin Therapy and Cancer in another window
Journal Articles

Safety of PPAR Agonists

Philip Home, DM
Journal: Diabetes Care
Diabetes Care 2011;34(Supplement_2):S215–S219
https://doi.org/10.2337/dc11-s233
Published: 22 April 2011
View article titled, Safety of PPAR Agonists
Open the PDF for Safety of PPAR Agonists in another window
Journal Articles

Should A1C Targets Be Individualized for All People With Diabetes?: Arguments for and against

Hwee Teoh, PHD, Philip Home, DM, Lawrence A. Leiter, MD
Journal: Diabetes Care
Diabetes Care 2011;34(Supplement_2):S191–S196
https://doi.org/10.2337/dc11-s217
Published: 22 April 2011
View article titled, Should A1C Targets Be Individualized for All People With Diabetes?: <subtitle>Arguments for and against</subtitle>
Open the PDF for Should A1C Targets Be Individualized for All People With Diabetes?: <subtitle>Arguments for and against</subtitle> in another window
Journal Articles

Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas?

Ebaa Al-Ozairi, MD, Latika Sibal, MD, Philip Home, MA, DM, DPHIL
Journal: Diabetes Care
Diabetes Care 2007;30(6):1677–1680
https://doi.org/10.2337/dc07-0339
Published: 01 June 2007
View article titled, Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas?
Open the PDF for Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): Good for Sulfonylureas? in another window
Journal Articles

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

Kjeld Hermansen, MD, Melanie Davies, MD, Taudeusz Derezinski, MD, Gabrielle Martinez Ravn, Per Clauson, Philip Home, DM, DPHIL, on behalf of the Levemir Treat-to-Target Study Group
Journal: Diabetes Care
Diabetes Care 2006;29(6):1269–1274
https://doi.org/10.2337/dc05-1365
Published: 01 June 2006
View article titled, A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes
Open the PDF for A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial

Philip Home, DM, DPHIL, Paul Bartley, MB, BS, FRACP, FACE, David Russell-Jones, MD, Hélène Hanaire-Broutin, MD, Jan-Evert Heeg, MD, Pascale Abrams, MD, Mona Landin-Olsson, MD, Birgitte Hylleberg, MSC, Hanne Lang, MSC, PHARM, Eberhard Draeger, PHD, on behalf of the Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (Steadiness) Study Group
Journal: Diabetes Care
Diabetes Care 2004;27(5):1081–1087
https://doi.org/10.2337/diacare.27.5.1081
Published: 01 May 2004
View article titled, Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: <subtitle>A randomized clinical trial </subtitle>
Open the PDF for Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: <subtitle>A randomized clinical trial </subtitle> in another window
Journal Articles

Potency of Insulin

Philip Home, DPHIL, MRCP
Journal: Diabetes Care
Diabetes Care 1988;11(7):604
https://doi.org/10.2337/diacare.11.7.604
Published: 01 July 1988
View article titled, Potency of Insulin
Open the PDF for Potency of Insulin in another window